The UK Biotech Sector and Brexit: Past Performance and Future Prospects

Sir Geoffrey Owen;Michael Hopkins

Seminar Briefing from Office of Health Economics

Abstract: This seminar briefing examines (1) why the UK has not produced large biotech firms that develop drugs, similar to those in the United States (US), (2) why the UK biotech firms that do exist have not brought blockbuster drugs to the market and (3) what the implications are for industrial strategy after Brexit. These remarks are based primarily on research we completed for our recent book, Science, the State and the City (Owen and Hopkins, 2016), with some additions and specific observations about the potential effects of Brexit. This seminar briefing examines (1) why the UK has not produced large biotech firms that develop drugs, similar to those in the United States (US), (2) why the UK biotech firms that do exist have not brought blockbuster drugs to the market and (3) what the implications are for industrial strategy after Brexit. These remarks are based primarily on research we completed for our recent book, Science, the State and the City (Owen and Hopkins, 2016), with some additions and specific observations about the potential effects of Brexit.

Keywords: The; UK; Biotech; Sector; and; Brexit:; Past; Performance; and; Future; Prospects (search for similar items in EconPapers)
JEL-codes: I1 (search for similar items in EconPapers)
Date: 2018-04-01
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.ohe.org/publications/uk-biotech-sector ... hment-seminar-23-v6/ (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ohe:sembri:002000

Access Statistics for this paper

More papers in Seminar Briefing from Office of Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ( this e-mail address is bad, please contact ).